Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Clinical trial NCT04271813 · COMPLETED

Trial details

NCT number: NCT04271813
Sponsor: Shanghai Changzheng Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Cancer Immunotherapy Anlotinib Sintilimab Chemo-free Therapy First-line Treatment

Start date: 2020-06-01
Primary completion: 2023-09-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.